Circulating tumor DNA (ctDNA) dynamics and survival outcomes in patients with advanced NSCLC and high (≥50%) PD-L1 expression
Read More
Poster
The resources in this stream include various studies in cfDNA and ctDNA.
-
-
SGO 2023 - Post-surgical ctDNA-based Molecular Residual Disease Detection in Patients with Stage I Endometrial Malignancies
Read More
-
SGO 2023 - Immunotherapy response monitoring using personalized circulating tumor DNA analysis
Read More
-
Performance of Donor-Derived Cell-Free DNA in Repeat Kidney Transplant Recipients
Read More
-
Elevations from Baseline dd-cfDNA Fraction are Associated with Acute Allograft Rejection in Kidney Transplant Recipients
Read More
-
Donor-Derived cfDNA Fraction Levels in Stable Kidney Transplant Recipients in the First Year After Transplant
Read More
-
Utility of circulating tumor DNA in monitoring treatment response to immune checkpoint inhibitors
Read More
-
Longitudinal detection of circulating tumor DNA in patients with advanced renal cell carcinoma
Read More
-
Utility of circulating tumor DNA in predicting outcome and pathological complete response in bladder cancer
Read More
-
Circulating tumor DNA (ctDNA) informs clinical practice in patients with recurrent metastatic gastroesophageal cancers
Read More
-
Circulating Tumor DNA as a Marker of Recurrence Risk in Locoregional Esophagogastric Cancers with Pathologic Complete Response
Read More
-
Feasibility and Dynamics of Preoperative Circulating Tumor DNA in Gastroesophageal Cancer Patients Receiving Preoperative Treatment
Read More
-
Implementation and outcomes of population-based hereditary cancer testing across a diverse multi-location breast imaging center
Read More
-
Cell-free DNA monitoring in a phase II study of adjuvant endocrine therapy with CDK 4/6 inhibitor ribociclib
Read More
-
Monitoring for response and recurrence in neoadjuvant-treated hormone receptor-positive HER2-negative breast cancer
Read More
-
Asco 2022 Monitoring Efficacy of Neoadjuvant Sunitinib in Metastatic Renal Cell Carcinoma
Read More
-
ASCO GU 2022 Molecular residual disease (MRD) detection with a tissue comprehensive genomic profiling (CGP)-informed personalized monitoring
Read More
-
Serial postoperative ctDNA monitoring of breast cancer recurrence
Read More
-
Comparison of the predictive and prognostic significance of circulating tumor DNA
Read More
-
Personalized Circulating tumor DNA as a Predictive Biomarker in High-Risk Early Stage Breast Cancer Treated With Neoadjuvant Chemotherapy
Read More
-
Loading More...
